Physician profile
Choo Lee
NPI 1649271818
$9,624.49
in general payments reported to CMS, 2019-2025
39 companies · $1,499 in 2025
The $1,499 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $913 · 2020: $1,285 · 2021: $1,797 · 2022: $1,411 · 2023: $1,169 · 2024: $1,551 · 2025: $1,499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,216 · Education: $2.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,216.08 |
| Education | $2.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $765.51 | 2019-2024 | Austedo Xr, Ajovy, Austedo |
| Ucb, INC. | $745.60 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Biogen, INC. | $721.06 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Abbvie INC. | $699.38 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $665.03 | 2019-2025 | |
| Emd Serono, INC. | $644.71 | 2019-2025 | Mavenclad |
| Pfizer INC. | $587.69 | 2019-2025 | |
| Upsher-Smith Laboratories LLC | $360.72 | 2020-2023 | |
| Eisai INC. | $354.33 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $332.81 | 2024-2025 | Ultomiris |
| Acadia Pharmaceuticals INC | $326.00 | 2019-2023 | Nuplazid |
| Allergan, INC. | $317.82 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $310.49 | 2022-2023 | Xarelto |
| Celgene Corporation | $265.92 | 2020-2025 | Zeposia |
| Biohaven Pharmaceuticals, INC. | $256.83 | 2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Choo Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.